GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » Cyclically Adjusted Revenue per Share

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Cyclically Adjusted Revenue per Share : $0.00 (As of Sep. 2022)


View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AVEO Pharmaceuticals's adjusted revenue per share for the three months ended in Sep. 2022 was $0.880. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Sep. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-06), AVEO Pharmaceuticals's current stock price is $15.00. AVEO Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 was $0.00. AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .


AVEO Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for AVEO Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

AVEO Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AVEO Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVEO Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



AVEO Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AVEO Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2022 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.88/125.2265*125.2265
=0.880

Current CPI (Sep. 2022) = 125.2265.

AVEO Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 3.571 96.871 4.616
201303 0.065 98.209 0.083
201306 0.063 98.518 0.080
201309 0.063 98.790 0.080
201312 0.063 98.326 0.080
201403 2.961 99.695 3.719
201406 0.357 100.560 0.445
201409 0.169 100.428 0.211
201412 0.021 99.070 0.027
201503 0.025 99.621 0.031
201506 0.024 100.684 0.030
201509 2.658 100.392 3.316
201512 0.619 99.792 0.777
201603 0.207 100.470 0.258
201606 0.029 101.688 0.036
201609 0.131 101.861 0.161
201612 0.017 101.863 0.021
201703 0.332 102.862 0.404
201706 0.032 103.349 0.039
201709 0.391 104.136 0.470
201712 0.007 104.011 0.008
201803 0.086 105.290 0.102
201806 0.034 106.317 0.040
201809 0.205 106.507 0.241
201812 0.090 105.998 0.106
201903 0.121 107.251 0.141
201906 0.044 108.070 0.051
201909 1.599 108.329 1.848
201912 0.047 108.420 0.054
202003 0.049 108.902 0.056
202006 0.043 108.767 0.050
202009 0.139 109.815 0.159
202012 0.034 109.897 0.039
202103 0.070 111.754 0.078
202106 0.220 114.631 0.240
202109 0.441 115.734 0.477
202112 0.513 117.630 0.546
202203 0.607 121.301 0.627
202206 0.733 125.017 0.734
202209 0.880 125.227 0.880

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


AVEO Pharmaceuticals  (NAS:AVEO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AVEO Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Executives
Jebediah Ledell officer: Chief Operating Officer C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey director, officer: President & CEO IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso officer: Chief Commercial Officer AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell 10 percent owner
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera officer: Chief Financial Officer 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring director AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Headlines

From GuruFocus

AVEO Oncology Stockholders Approve Acquisition by LG Chem

By Stock market mentor Stock market mentor 01-06-2023